ALLOX has raised $10.5 million to find a drug where conventional chemistry cannot. The Barcelona-based biotech, spun out of the Centre for Genomic Regulation (CRG) in 2023, is betting its computational platform can identify and drug allosteric sites, the regulatory pockets on proteins that act like biological switches [ALLOX, November 2023]. The initial target is oncology, a field where many disease-causing proteins remain stubbornly undruggable because their active sites are either missing or too difficult to block [El Periódico, October 2026].
The Allosteric Wedge
Most drug discovery focuses on a protein's active site, the obvious pocket where biological activity happens. ALLOX is targeting the allosteric site, a separate location that, when bound by a molecule, can alter the protein's function elsewhere [ALLOX, November 2023]. The company describes these as "the switches" controlling disease-relevant proteins [El Periódico, October 2026]. Its proprietary platform combines three elements: experimental genetics to understand protein function, artificial intelligence for prediction, and energy-based models for molecular design [ALLOX, November 2023]. The goal is not to sell software but to use this integrated engine to build an internal pipeline of therapeutic programs, with the first aimed at cancers [ALLOX, May 2025].
A Lab Spinout With Institutional Backing
The company is a direct product of Ben Lehner's laboratory at the CRG. All four co-founders are alumni, creating a tight link between foundational research and commercial application. The leadership team brings a blend of computational and biological expertise.
| Role | Name | Background |
|---|---|---|
| CEO & Co-founder | Júlia Domingo | Biologist and bioinformatician; PhD in Lehner's lab [ALLOX]. |
| Chief Scientific Advisor & Co-founder | Ben Lehner | ICREA professor, Head of Generative Genomics at Wellcome Sanger Institute [ALLOX, May 2025]. |
| Chief Discovery Officer & Co-founder | Pablo Baeza | Computational biochemist and data scientist; PhD in Lehner's lab [ALLOX]. |
| Chief Development Officer & Co-founder | André Faure | Former postdoctoral researcher and staff scientist in Lehner's lab [ALLOX, May 2025]. |
This academic pedigree attracted a specific type of capital. The recent $10.5 million seed round was led by Asabys Partners through its Sabadell Asabys II fund and included participation from Spanish public entities CDTI (via SICC Innvierte) and the Institut Català de Finances (ICF) [GlobeNewswire, October 2026]. The round also brought in Morten Graugaard, a life sciences investor and former Novo Holdings director, as chair of the board [ALLOX, October 2026]. The capital mix signals confidence in both the science and its potential to grow within Catalonia's biotech ecosystem.
The Capital Stack and the Clock
The disclosed $10.5 million brings ALLOX's total known financing to at least that figure, following an undisclosed pre-seed from Asabys in late 2023 [ALLOX, November 2023]. The company has also reported a separate, undisclosed venture round led by Zerra Ventures [Crunchbase, retrieved 2026]. This funding provides a multi-year runway for a business facing the long timelines inherent to drug discovery. The immediate use of proceeds is to scale the discovery platform and advance its internal pipeline [GlobeNewswire, October 2026]. The appointment of Graugaard, with his background in R&D and business development, points to a strategy that may later include partnership discussions with larger pharma companies [ALLOX, October 2026].
Where the Wheels Could Come Off
The ambition is clear, but the path is lined with risks inherent to the category. ALLOX is operating in one of the most capital-intensive and high-failure-rate sectors in technology.
- Technical validation. The core premise,reliably predicting and drugging allosteric sites with a novel platform,remains unproven at the scale needed for a clinical asset. Success depends on the platform generating high-quality leads that can navigate preclinical development.
- The translational gap. Moving from a computational prediction or a lab-validated switch to a safe, effective drug candidate is a monumental leap. The company's team, while strong in discovery science, will need to bolster its development and clinical operations expertise as programs advance.
- Competitive intensity. While its approach is specialized, ALLOX is not alone in pursuing allosteric drug discovery. It lists ALX Oncology, Allogene Therapeutics, and Allos Therapeutics as competitors, though each has a different therapeutic focus and modality. The broader field of computational drug discovery is also crowded with well-funded players.
The company's most plausible answer to these risks is its integrated model. By controlling the platform and the pipeline, it aims to iterate rapidly and capture the full value of any successful discovery, rather than licensing early-stage assets [ALLOX, May 2025]. The deep academic roots and specialized investor base provide a foundation of patience and scientific credibility that pure software startups often lack.
The Next Twelve Months
For ALLOX, the clock started with the October 2026 seed close. The next year will be about deploying that $10.5 million to generate the data that validates,or challenges,the platform's predictive power. Key milestones will be internal: selecting a lead program, generating compelling in vitro and in vivo proof-of-concept data, and potentially filing its first patent applications. Externally, watch for strategic hires in drug development and any early research collaborations that signal external validation of its approach. The bet from Asabys, CDTI, and ICF is a substantial one for a European biotech spinout. The question for the market now is whether ALLOX can translate its academic insights on protein "kill switches" into a clinical candidate that turns the biology of cancer off.
Sources
- [ALLOX, November 2023] ALLOX launches with the support of Asabys | https://www.allox.bio/news/allox-launches-with-the-support-of-asabys
- [El Periódico, October 2026] ALLOX technology identifies switches to stop diseases | https://www.elperiodico.com/es/economia/20261029/allox-tecnologia-catalana-identifica-interruptores-frenar-enfermedades-135831073
- [ALLOX, May 2025] ALLOX, the startup using allostery to rework drug development | https://www.allox.bio/news/allox-the-startup-using-allostery-to-rework-drug-development
- [GlobeNewswire, October 2026] ALLOX closes $10.5M seed financing and appoints Morten Graugaard as chair | https://www.globenewswire.com/news-release/2026/10/29/3390985/0/en/allox-closes-10-5m-seed-financing-and-appoints-morten-graugaard-as-chair-to-scale-allosteric-drug-discovery-platform-and-build-pipeline.html
- [Crunchbase, retrieved 2026] ALLOX Company Profile | https://tracxn.com/d/companies/allox/__zYDFXaPubEOW0DM3wa1Nb8pvEYKg24INud3O0Bk6BJE